3030200-17-7
Chemical Structure
Peptide 22
- CAS No.: 3030200-17-7
- Formula:C75H96N16O20
- Molecular Weight:1541.66
InChIKey: OMHLWXANZNMPPJ-WCNSOSDNSA-N
SMILES: O=C(N[C@@H](CC1=CNC=N1)C(N[C@@H](CC2=CNC3=CC=CC=C23)C(N[C@@H](CC4=CC=C(C=C4)O)C(NCC(N[C@@H](CC5=CC=C(C=C5)O)C(N[C@@H]([C@H](O)C)C(N6[C@@H](CCC6)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](C(C)C)C(N[C@@H]([C@@H](C)CC)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC7=CC=C(C=C7)O)N
Biological Activity: Peptide 22 is a polypeptide that binds to EGFR. Peptide 22 competes with endogenous EGF for EGFR binding sites and is taken up by triple-negative breast cancer cells in a dose-dependent manner. Peptide 22 can be used in studies related to triple-negative breast cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Peptide 22 | Peptide 22 is a polypeptide that binds to EGFR. Peptide 22 competes with endogenous EGF for EGFR binding sites and is taken up by triple-negative breast cancer cells in a dose-dependent manner. Peptide 22 can be used in studies related to triple-negative breast cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Nag A, et al. Fluorescent Sensors of Phosphate Containing Biomolecules. Israel Journal of Chemistry. 2020 Dec 09;61(3-4):169-184.
- [2]. Nisticò N, et al. Development of Cyclic Peptides Targeting the Epidermal Growth Factor Receptor in Mesenchymal Triple-Negative Breast Cancer Subtype. Cells. 2023 Apr 03;12(7):1078. [Content Brief]
